Logo

RDHL

RedHill Biopharma Ltd.

RDHL

RedHill Biopharma Ltd. • NASDAQ
$1.20 ▲ 10.09% (+0.11)
Market Cap $4.00 M
52w High $8.75
52w Low $1.01
Dividend Yield 0%
P/E 0
Volume 67.76K
Outstanding Shares 3.33M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $2.039M $3.425M $-2.067M -101.324% $-1 $-2.105M
Q1-2025 $2.039M ▼ $3.425M ▼ $-2.067M ▲ -101.324% ▼ $-1 $-2.105M ▼
Q4-2024 $2.736M $4.924M $-2.59M -94.681% $-1 $-1.879M ▼
Q3-2024 $2.736M ▲ $4.924M ▲ $-2.59M ▼ -94.681% ▲ $-1 $-1.817M ▲
Q2-2024 $1.286M $4.808M $-1.544M -120.062% $-1 $-4.015M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $2.866M $18.375M $22.787M $-4.412M
Q1-2025 $2.866M ▼ $18.375M ▲ $22.787M ▲ $-4.412M ▲
Q4-2024 $4.617M $18.043M $22.726M $-4.683M
Q3-2024 $4.617M ▼ $18.043M ▼ $22.726M ▲ $-4.683M ▼
Q2-2024 $7.277M $22.024M $21.963M $61K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2.067M $-2.507M $-2K $1.629M $0 $-2.509M
Q1-2025 $-2.067M ▲ $-2.507M ▼ $-2K ▲ $1.629M ▲ $0 $-2.509M ▼
Q4-2024 $-2.59M $-1.592M $-4K $258.5K $0 ▲ $-1.596M
Q3-2024 $-2.59M ▼ $-1.592M ▲ $-4K ▼ $258.5K ▼ $-7.277M ▼ $-1.596M ▲
Q2-2024 $-1.544M $-3.092M $-500 $3.95M $7.277M $-3.093M

Revenue by Products

Product Q2-2020Q2-2021Q2-2022
Movantik
Movantik
 $20.00M ▲$20.00M ▲$20.00M ▲

Five-Year Company Overview

Income Statement

Income Statement The company’s sales base is very small and has not yet scaled in a way that supports a self-sustaining business. Gross profit exists but is modest, and operating results have mostly been in loss territory, with just a brief improvement recently that does not yet look firmly established. Earnings per share figures appear extremely volatile, largely because of reverse stock splits and capital changes, rather than underlying business strength. Overall, the income statement tells the story of a company still in the development stage, with high dependence on future product uptake and pipeline success to improve profitability.

Balance Sheet

Balance Sheet The balance sheet has shrunk considerably over the past few years, reflecting asset sales, write-downs, or a much leaner operating structure. Cash levels are low relative to the company’s needs, even though formal debt has largely been reduced or eliminated more recently. Shareholders’ equity has hovered around breakeven and was negative at one point, which signals past accumulated losses and a thin capital cushion. This balance-sheet profile suggests financial fragility and a strong reliance on external funding, partnerships, or successful commercialization to stabilize the capital base.

Cash Flow

Cash Flow Cash flow from day-to-day operations has been consistently negative, which is typical for a small biopharma still investing in development and commercialization. Free cash flow has also been negative across all years, although spending on physical assets is quite limited, indicating that most cash burn is tied to R&D, trials, and operating expenses rather than heavy equipment or facilities. This pattern means the company is not yet funding itself through its own activities and has likely depended on equity issuance, restructuring, licensing, or other financing sources to keep going. Sustained progress in reducing this cash burn will be critical to extending its financial runway.

Competitive Edge

Competitive Edge RedHill operates in specialized gastrointestinal and infectious disease niches, which reduces direct head‑to‑head competition with the largest global drug makers. It has one approved product, Talicia, in a clearly defined infection where resistance to older therapies is a real concern, giving it a differentiated clinical angle. The company’s pipeline, including RHB‑204 and its host‑directed antivirals, targets areas with high unmet medical need and potential regulatory support, which can be a competitive advantage. That said, its small size, limited commercial footprint, and constrained finances make it vulnerable when facing larger competitors, pricing pressure, and reimbursement hurdles, especially if clinical or regulatory timelines slip.

Innovation and R&D

Innovation and R&D Innovation is a clear focal point: the company is pursuing novel combinations and mechanisms in GI diseases and infectious conditions, including antibiotic-resistant infections, Crohn’s disease with a possible infectious trigger, and host‑directed antivirals. The intellectual property around Talicia and the pipeline candidates, along with regulatory designations like Fast Track, QIDP, and Orphan status, provides meaningful protection and potential exclusivity if products reach or expand in the market. The pipeline is relatively advanced compared with many early‑stage biotech peers, which can lower scientific risk somewhat, but substantial clinical, regulatory, and commercial risks remain until larger, confirmatory data sets are available. Ongoing R&D efforts will require careful balancing of ambition with financial discipline and strategic partnering to avoid overextension.

Summary

Overall, RedHill Biopharma looks like a high‑innovation, high‑risk small biopharma with a narrow commercial base. The company has carved out differentiated positions in GI and infectious diseases, backed by patents and regulatory incentives, and it is pursuing approaches that could address meaningful unmet needs. At the same time, the financial picture is strained: revenues are small, profitability is not yet durable, cash flows are negative, and the balance sheet is thin. The future trajectory will largely depend on clinical and regulatory outcomes for its key pipeline assets, the commercial traction of Talicia, and the company’s ability to secure funding and partnerships without overly diluting existing stakeholders. Uncertainty is high, but so is the potential impact if even one or two of its late‑stage programs succeed and are successfully commercialized.

NEWS

November 4, 2025 · 9:30 AM UTC

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Read more

October 22, 2025 · 4:50 PM UTC

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Read more

October 20, 2025 · 9:05 AM UTC

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Read more

October 6, 2025 · 8:00 AM UTC

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

Read more

September 29, 2025 · 7:00 AM UTC

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Read more